Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016923
Chunk: 66

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 66
---
,000 in proceeds upon such exercise, our pro forma as adjusted net tangible book value as of March 31, 2025 would have been $15.5 million, or $0.47 per share. This represents an immediate increase in pro forma net tangible book value of $0.40 per share to existing stockholders and an immediate dilution in net tangible book value of $2.59 per share to investors purchasing from holders of the Tradeable Warrants, Non-Tradeable Warrants and Representative’s Warrants and $6.88 per share to investors purchasing from holders of the Placement Agent Warrants.

The following table illustrates the per share dilution to investors purchasing shares in an offering using this prospectus:

| Exercise price of Tradeable Warrant, Non-Tradeable Warrant and Representative’s Warrants                                                                       
 Exercise price of Placement Agent Warrants                                                                                                                     
 Net tangible book value per share as of March 31, 2025                                                                                                         |     |   | (0.04 | ) |     |   | 3.0625 
   7.35 |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--|------:|:--|:----|:--|-------:|
| Pro forma net tangible book value per share                                                                                                                    |     | $ |  0.07 |   |     |   |        |
| Increase in pro forma net tangible book value per share attributable to this offering                                                                          |     | $ |  0.40 |   |     |   |        |
| Pro forma as adjusted net tangible book value per share after this offering                                                                                    |     |   |       |   |     | $ |   0.47 |
| Dilution in net tangible book value per share to investors purchasing from holders of Tradeable Warrants, Non-Tradeable Warrants and Representative’s Warrants |     |   |       |   |     | $ |   2.59 |
| Dilution in net tangible book value per share to investors purchasing from holders of Placement Agent Warrants                                                 |     |   |       |   |     | $ |   6.88 |

The information above is based on 18,255,825 shares of Common Stock outstanding as of March 31, 2025, and excludes, as of that date:

| ● | 12,873,602                                                                                                                          
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $2.74